FIELD: medicine.
SUBSTANCE: method involves subcutaneously introducing recombinant human granulocytic colony-stimulating factor to an animal at a dose of 100 mcg/kg of body weight once a day during 5 days.
EFFECT: enhanced effectiveness in restoring functionally active muscle tissue.
2 dwg, 1 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREVENTING POSTINFARCTION CARDIAC REMODELING IN EXPERIMENT | 2016 |
|
RU2634375C2 |
HYPOLIPIDEMIC AND ANTIISHEMIC AGENT "SERPYSTEN" | 2007 |
|
RU2337701C1 |
METHOD FOR TREATING EXPERIMENTAL CHRONIC TOXIC HEPATITIS | 2005 |
|
RU2295971C1 |
CORONARY ACTIVE ANTI-ISCHEMIA AND ANTI-ARRHYTHMIA AGENT | 2005 |
|
RU2290927C1 |
TRANSLATIONAL MODEL OF CHRONIC HEART FAILURE: THE METHOD AND CRITERIA OF FORMATION ASSESSMENT | 2018 |
|
RU2744681C1 |
ANTI-ISCHEMIC DRUG | 2012 |
|
RU2499593C1 |
METHOD FOR CARRYING OUT EXPERIMENTAL ENCEPHALOPATHY THERAPY | 2004 |
|
RU2284060C1 |
METHOD FOR MODELLING MYOCARDIAL INFARCTION | 0 |
|
SU731958A1 |
METHOD OF POSTINFARCTION REMODELLED CARDIAC MUSCLE PREPARATION FOR INTRAMYOCARDIAL CELL TRANSPLANTATION IN EXPERIMENT | 2009 |
|
RU2412658C2 |
ANTI-ISHEMIC AND ANTIHYPOXIC AGENT | 2007 |
|
RU2356573C1 |
Authors
Dates
2006-12-10—Published
2005-02-14—Filed